Fundraising goal of 32,000 euros to ensure the survival of a 22-year-old female patient
Headline: Promising Immunologic Treatment for Lung Synovial Sarcoma Patient Anastasia Maisternko
In a heartwarming appeal for support, the family of 12-year-old Anastasia Maisternko, a resident of Minsk, Belarus, has shared her ongoing battle with a rare form of cancer known as synovial sarcoma. The disease has metastasised to her lungs, but hope remains as a promising immunologic treatment, afamitresgene autoleucel (Tecelra or afami-cel), shows significant effectiveness, particularly in advanced or metastatic cases.
Contact Information For those wishing to extend their support, contact information has been provided. Anatoly, Anastasia's father, can be reached at home on 375 17 344-81-67 or via mobile at 375 29 761-43-01.
Payment Details Funds for the treatment can be transferred to MTS balance on the number +37529 761-43-01 (Anatoly, Anastasia's father). These funds will then be transferred to Easypay or WebMoney through the ipay service, specifically for Maistrenko Anatoly Ivanovich for the treatment of Maistrenko Anastasia. The Easypay number is 34581035.
WebMoney account numbers for various currencies are as follows: - Belarusian rubles: B625412940729 - US dollars: Z260248209493 - Euros: E327962315234 - Russian rubles: R106302547971
Treatment Options Afami-cel is a one-time, personalized engineered cell therapy designed to enhance the immune system to target cancer cells expressing the MAGE-A4 antigen, which is common in synovial sarcoma. Clinical trials demonstrated a 43% overall response rate in patients with advanced synovial sarcoma, marking a significant advancement since no effective immunotherapy options existed for over a decade.
Other immune checkpoint inhibitors, such as pembrolizumab, have shown limited efficacy as monotherapy in sarcomas including synovial sarcoma, with very low objective response rates (between 0% and 18% depending on subtype). Combination therapies involving pembrolizumab may improve efficacy but with higher toxicity and variable outcomes. Therefore, checkpoint inhibitors alone are generally less effective compared to afami-cel in synovial sarcoma.
Emerging treatments like tigilanol tiglate (Stelfonta) have exhibited high response rates (~80%) in advanced soft tissue sarcomas but these data primarily come from early-phase trials and may not be specific to synovial sarcoma or lung metastases.
In summary, for a patient like Anastasia Maisternko with synovial sarcoma in the lungs, afami-cel (Tecelra) represents the most promising immunologic treatment currently available, with demonstrated meaningful responses in advanced disease when MAGE-A4 is expressed. Other immunotherapies such as pembrolizumab have limited effectiveness in this sarcoma subtype. Treatment suitability and effectiveness depend on molecular tumor profiling (e.g., MAGE-A4 and HLA compatibility) and clinical trial eligibility.
Mailing Address For those who wish to send letters or cards, they can be addressed to Svetlana Emilevna Maistrenko at 220075, Minsk, ul. Bachilo, 21-107.
As the family continues to navigate this challenging journey, the community's support is greatly appreciated. Every donation brings hope and moves Anastasia one step closer to a brighter future.
- Anastasia Maisternko's family mentioned that a promising immunologic treatment, called afamitresgene autoleucel (Tecelra or afami-cel), has shown significant effectiveness for her advanced lung synovial sarcoma.
- Clinical trials have demonstrated a 43% overall response rate for afami-cel in patients with advanced synovial sarcoma, a significant advancement in immunotherapy options for this condition.
- Other immunotherapies, such as pembrolizumab, have shown limited efficacy as monotherapy in the treatment of synovial sarcoma compared to afami-cel.
